Zobrazeno 1 - 10
of 185
pro vyhledávání: '"Gkotzamanidou, M."'
Autor:
Psyrri, A., Gkotzamanidou, M., Papaxoinis, G., Krikoni, L., Economopoulou, P., Kotsantis, I., Anastasiou, M., Souliotis, V.L.
Publikováno v:
In ESMO Open April 2021 6(2)
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S769-S769
Autor:
Terpos, E. *, Kastritis, E., Christoulas, D., Gkotzamanidou, M., Eleutherakis-Papaiakovou, E., Kanellias, N., Papatheodorou, A., Dimopoulos, M.A.
Publikováno v:
In Annals of Oncology October 2012 23(10):2681-2686
Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells, and accounts for 10% of all hematologic malignancies and 1% of all cancers. MM is characterized by genomic instability which results from DNA damage with certain genomic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::3fee623c86364020bae98de88d4d1f53
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2980667
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2980667
Background: We sought to compare patterns of response to immune checkpoint inhibitors (ICI) with respect to clinical and genomic features in a retrospective cohort of patients with recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::1dd9cbc2528ae523a5b929650bb3605f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076666
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076666
Background: We sought to determine whether DNA damage response (DDR)-related aberrations predict therapeutic benefit in cisplatin-treated head and neck squamous cell carcinoma (HNSCC) patients and how DDR pathways are modulated after treatment with o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::35ee2c47e1ffff616348ba70a8ba5562
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076400
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076400
Background We sought to determine the prognostic role of indoleamine 2,3-dioxygenase 1 (IDO1) by evaluating IDO1 expression in circulating tumour cells (CTCs) at baseline and after completion of chemoradiotherapy in patients with locally advanced (LA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::1c81faefd975d73b7639ca87e6960cd3
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078053
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078053
Autor:
Gkotzamanidou, M., Sfikakis, P. P., Kyrtopoulos, S. A., Bamia, C., Dimopoulos, M. A., Souliotis, V. L.
Publikováno v:
Br J Cancer
Melphalan is one of the most active chemotherapeutic agents in the treatment of multiple myeloma (MM). However, the mechanism underlying differential patient responses to melphalan therapy is unknown.Chromatin structure, transcriptional activity and
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.